ARCT
USDArcturus Therapeutics Holdings Inc. Common Stock
Цена в режиме реального времени
График цен
Ключевые показатели
Рыночные показатели
Открытие
$9.170
Максимум
$9.400
Минимум
$8.840
Объем
1.18M
Фундаментальные показатели компании
Рыночная капитализация
242.5M
Отрасль
Биотехнология
Страна
United States
Статистические данные торговли
Средний объем
1.22M
Биржа
NGM
Валюта
USD
52-недельный диапазон
Связанные новости
HC Wainwright & Co. Downgrades Arcturus Therapeutics to Neutral, Lowers Price Target to $12
HC Wainwright & Co. analyst Andrew S. Fein downgrades Arcturus Therapeutics from Buy to Neutral and lowers the price target from $60 to $12.
Citigroup Downgrades Arcturus Therapeutics to Neutral, Lowers Price Target to $12
Citigroup analyst Yigal Nochomovitz downgrades Arcturus Therapeutics from Buy to Neutral and lowers the price target from $49 to $12.
Arcturus' Investigational Inhaled Therapy Lacks Meaningful Lung Function Improvement, Analyst Notes Mixed Picture
Arcturus stock drops on interim Phase 2 results for ARCT-032, showing promising mucus reduction in cystic fibrosis patients but no initial FEV₁ improvement.
BTIG Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $23
BTIG analyst Thomas Shrader maintains Arcturus Therapeutics with a Buy and lowers the price target from $48 to $23.
Guggenheim Downgrades Arcturus Therapeutics to Neutral
Guggenheim analyst Seamus Fernandez downgrades Arcturus Therapeutics from Buy to Neutral.
Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program
ARCT-032 generally safe and well tolerated Meaningful trends of clinical activity observed via high resolution CT scans After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class I CF participants
Связанные акции
Оставаться в курсе
Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.